Journal of Cancer Diagnosis
Open Access

Uterine cancer; Endometrial carcinoma; Uterine sarcoma; Diagnostic modalities; Transvaginal ultrasound; Hysteroscopy; Magnetic resonance imaging (MRI); Endometrial biopsy; Curettage; Biomarkers; Genetic testing; Personalized medicine; Diagnostic accuracy; Staging; Treatment planning

Introduction

Uterine cancer, also known as endometrial cancer, is a type of cancer that originates in the lining of the uterus, called the endometrium. It is one of the most common cancers of the female reproductive organs and typically affects women in their 50s and 60s. Early diagnosis is crucial for effective treatment and better outcomes [1]. This article provides an in-depth look at the methods and procedures used to diagnose uterine cancer.

Uterine cancer is a prevalent malignancy within the realm of gynaecologic oncology, representing one of the most common cancers affecting the female reproductive system. It predominantly manifests as endometrial cancer, which originates from the lining of the uterus, but it also includes uterine sarcomas, a rarer and more aggressive form [2]. The increasing incidence of uterine cancer, coupled with its potential for varied presentation, underscores the necessity for a robust and comprehensive diagnostic framework. The early and accurate diagnosis of uterine cancer is crucial for effective management and improved survival rates [3]. The diagnostic process typically begins with a detailed patient history and physical examination, which can provide initial clues about the presence of uterine cancer [4]. This is followed by various imaging techniques designed to evaluate the extent of the disease and to aid in the differentiation between benign and malignant conditions. Transvaginal ultrasound, often the first imaging modality used, offers valuable information regarding uterine morphology and endometrial thickness. However, for more detailed assessment, magnetic resonance imaging (MRI) plays a pivotal role in delineating tumor boundaries, assessing local invasion, and guiding surgical planning [5].

Histological confirmation of uterine cancer is achieved through endometrial biopsy procedures, including endometrial sampling and dilation and curettage (D&C). These methods enable the evaluation of tissue samples for the presence of malignancy and are essential for accurate diagnosis and staging [6]. Advancements in biopsy techniques, such as the incorporation of molecular and genetic analyses, hold promise for enhancing diagnostic precision and personalizing treatment approaches [7].

The staging of uterine cancer, determined through a combination of imaging and histopathological evaluation, is critical for treatment planning and prognosis. The International Federation of Gynecology and Obstetrics (FIGO) staging system are widely used to classify the extent of disease spread and to guide therapeutic decisions [8].

Moreover, the evolving landscape of diagnostic technologies, including liquid biopsies and genomic profiling, offers exciting prospects for earlier detection and more precise diagnosis. These innovations may eventually lead to more individualized treatment strategies and better patient outcomes [9].

A comprehensive approach to the diagnosis of uterine cancer involves a combination of clinical evaluation, imaging, biopsy, and emerging diagnostic technologies. By understanding and integrating these elements, healthcare providers can improve diagnostic accuracy, facilitate early intervention, and enhance patient care [10].

Risk factors and symptoms

Understanding the risk factors and symptoms associated with uterine cancer can aid in early detection. Some common risk factors include:

Age: Most cases are diagnosed in women over 50.

Obesity: Excess body fat increases estrogen levels, which can contribute to the development of cancer.

Hormonal imbalances: Conditions such as polycystic ovary syndrome (PCOS) and estrogen replacement therapy can increase risk.

Family history: A history of uterine cancer or other cancers in the family can elevate risk.

Reproductive history: Women who have never been pregnant may have a higher risk.

Symptoms of uterine cancer often include:

• Abnormal vaginal bleeding or spotting, especially after menopause
• Pelvic pain or discomfort
• Pain during intercourse
• Abnormal vaginal discharge

Diagnostic procedures

Medical history and physical examination

The diagnostic process typically begins with a thorough medical history and physical examination. The healthcare provider will ask about symptoms, menstrual history, and any relevant family history of cancer. A pelvic exam may be conducted to check for abnormalities in the uterus, ovaries, and other pelvic organs.

Imaging tests

Imaging tests help visualize the uterus and other pelvic structures to identify potential abnormalities.

Transvaginal ultrasound (TVUS): This test uses sound waves to create images of the uterus. It is often used to assess the thickness of the endometrial lining, which can indicate abnormal growths or tumors.

Computed tomography (CT) scan: A CT scan provides detailed cross-sectional images of the pelvic region. It helps determine if the cancer has spread to other parts of the body.

Magnetic resonance imaging (MRI): MRI uses magnetic fields and radio waves to produce detailed images of the uterus and surrounding tissues. It is particularly useful for assessing the extent of cancer spread.

Endometrial biopsy

An endometrial biopsy involves taking a small sample of the endometrial tissue to examine for cancerous cells. This procedure is often performed in the doctor’s office using a thin, flexible tube inserted through the vagina and cervix.

D&C (dilation and curettage)

If the biopsy results are inconclusive, a D&C may be performed. During this procedure, the cervix is dilated, and a small instrument is used to scrape the lining of the uterus to collect tissue samples. This procedure is usually done under sedation.

Hysteroscopy

A hysteroscopy involves inserting a thin, lighted tube (hysteroscope) through the vagina and cervix to view the inside of the uterus. It allows for direct visualization of the endometrium and can be combined with a biopsy to obtain tissue samples.

Genetic testing

In some cases, genetic testing may be recommended, especially if there is a family history of uterine cancer or other related cancers. Testing can identify specific genetic mutations that may increase the risk of cancer.

Staging and grading

Once uterine cancer is diagnosed, further tests are conducted to determine the stage and grade of the cancer.

Staging: Staging describes the extent of cancer spread. The stages range from Stage 0 (pre-cancerous) to Stage IV (advanced cancer). Staging is based on the size of the tumor, its spread to nearby tissues, and involvement of lymph nodes or distant organs.

Grading: Grading assesses how abnormal the cancer cells look under a microscope. The grade indicates how quickly the cancer is likely to grow and spread. Uterine cancer is usually graded from 1 to 3, with Grade 1 being the least aggressive and Grade 3 being the most aggressive.

Conclusion

Early and accurate diagnosis of uterine cancer is essential for effective treatment and improved outcomes. If you experience any symptoms or have risk factors for uterine cancer, it is important to seek medical advice promptly. Regular screenings and awareness of symptoms can play a crucial role in early detection and successful management of the disease.

For anyone facing a diagnosis of uterine cancer, a multidisciplinary approach involving gynaecologists, oncologists, and other healthcare professionals will help in creating a personalized treatment plan and providing support throughout the treatment process. The diagnosis of uterine cancer is a multifaceted process that demands a thorough understanding of the disease, its risk factors, and the latest advancements in diagnostic technologies. As outlined in this comprehensive overview, uterine cancer, encompassing endometrial cancer and uterine sarcomas, presents a significant health challenge with its increasing incidence globally. Effective diagnosis is crucial for improving patient outcomes, and it involves a combination of clinical evaluation, imaging techniques, histopathological examination, and molecular testing.

The diagnosis of uterine cancer requires a multidisciplinary approach and an integration of various diagnostic tools and techniques. While current methods have significantly improved the accuracy of diagnosis and staging, ongoing research and technological advancements are crucial for further enhancing early detection and treatment. A collaborative effort between patients, healthcare providers, and researchers is essential to advance our understanding of uterine cancer and to ultimately improve patient outcomes. With continued progress in diagnostic technology and an emphasis on early detection, there is hope for more effective management and better survival rates for women affected by this challenging disease.

1. Ugai T, Sasamoto N, Ando HM, Song M, Tamimi RM, et al. (2022) Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nature Reviews Clinical Oncology 19:656-673.

Indexed at, Google Scholar, Crossref

2. Ryndock EJ, Meyers C (2014) A risk for non-sexual transmission of human papillomavirus? Expert Rev. Anti Infect Ther 12: 1165-1170.

Indexed at, Google Scholar, Crossref

3. Petca A, Borislavschi A, Zvanca ME, Petca R, Sandru F, et al. (2020) Non-sexual HPV transmission and role of vaccination for a better future (Review). Exp Ther Med 20: 186.

Indexed at, Google Scholar, Crossref

4. Castle PE, Maza M (2016) Prophylactic HPV vaccination: Past, present, and future. Epidemiol Infect 144: 449-468.

Indexed at, Google Scholar, Crossref

5. Park IU, Introcaso C, Dunne EF (2015) Human papillomavirus and genital warts: A review of the evidence for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 61: 849-855.

Indexed at, Google Scholar, Crossref

6. Boda D, Docea AO, Calina D, Ilie MA, Caruntu C, et al. (2018) Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). Int J Oncol 52: 637-655.

Indexed at, Google Scholar, Crossref

7. You W, Li S, Du r, Zheng J, Shen A (2018) Epidemiological study of high-risk human papillomavirus infection in subjects with abnormal cytological findings in cervical cancer screening. Exp Ther Med 15: 412-418.

Indexed at, Google Scholar, Crossref

8. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE (2011) the cost-effectiveness of male HPV vaccination in the United States. Vaccine 29: 8443-8450.

Indexed at, Google Scholar, Crossref

9. Burger EA, De Kok IMCM, Groene E, Killen J, Canfell K, et al. (2020) Estimating the Natural History of Cervical Carcinogenosis Using Simulation Models: A cisnet Comparative Analysis. J Natl Cancer Inst 112: 955-963.

Indexed at, Google Scholar, Crossref

10. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, et al. (2013) 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease 17: 1-27.

Indexed at, Google Scholar, Crossref